Home>Topics>>Vical's Allovectin: Update On The Phase III Trial
Vical's Allovectin: Update On The Phase III Trial
Healthcare Sector and Stocks Analysis from Seeking Alpha
Thu, 8 Nov 2012
By Theodore Cohen: In its press release Wednesday morning, November 7, 2012, Vical Incorporated ( VICL ) announced that a comprehensive sweep of all active clinical sites in its Phase 3 Allovectin melanoma trial - done to eliminate any time lag in death event reporting - co nfirmed the target ...
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.